Factor XIII A-subunit, recombinant

Drug Overview

Factor XIII A-subunit, recombinant is a highly specialized and life-saving medication utilized in the hematology category. Classified as a Coagulation Factor XIII, this advanced Biologic provides targeted treatment for one of the rarest bleeding disorders in the world. For patients born without the ability to form stable blood clots due to a specific genetic defect, this medication offers profound protection. Because it is manufactured in a laboratory rather than extracted from human blood, it entirely eliminates the risk of transmitting human blood-borne viruses, offering patients a safe and highly effective way to manage their chronic condition.

• Generic Name / Active Ingredient: Catridecacog (Factor XIII A-subunit, recombinant)
• US Brand Names: Tretten
• Drug Class: Coagulation Factor XIII / Antihemorrhagic Agent
• Route of Administration: Intravenous (IV) injection
• FDA Approval Status: Fully FDA-approved for adults and children.
  
  Discover facts on Factor XIII A-subunit, recombinant. Learn its specific medical uses, health benefits, side effects, and standard dosage.

What Is It and How Does It Work? (Mechanism of Action)

To understand how this Biologic works, it is helpful to visualize the final steps of the body’s natural blood-clotting process, known as the coagulation cascade. When a blood vessel is injured, the body forms a web of a protein called fibrin to plug the hole. However, a newly formed fibrin web is weak and easily broken down. Factor XIII is the final, critical enzyme in the cascade; it acts like the biological “glue” that cements the web together.

Natural Factor XIII is made of two parts: the A-subunit (the active part that does the gluing) and the B-subunit (a carrier that protects the A-subunit). Patients with congenital Factor XIII A-subunit deficiency have a genetic mutation preventing them from producing the active “glue.” As a result, their bodies can start forming a clot, but the clot breaks apart prematurely, leading to delayed, severe, and spontaneous bleeding, often days after a minor injury.

When a patient receives this recombinant medication, they are directly infused with laboratory-engineered A-subunits. Once in the bloodstream, this Biologic binds to the patient’s naturally occurring B-subunits. When an injury happens, the enzyme thrombin and calcium activate the medication. At a molecular level, the active Factor XIII creates strong chemical bonds (cross-links) between the fibrin strands. This reinforces the clot, making it physically hard, durable, and highly resistant to premature breakdown (fibrinolysis), successfully stopping the hemorrhage.

FDA-Approved Clinical Indications

Primary Indication

The primary clinical indication for recombinant Factor XIII A-subunit is routine prophylaxis (prevention) of bleeding in patients with congenital Factor XIII A-subunit deficiency. It is used to maintain a constant, safe level of Factor XIII in the blood, preventing spontaneous joint bleeds, soft tissue hemorrhages, and life-threatening intracranial (brain) bleeding that frequently occurs in these patients.

Other Approved & Off-Label Uses

• No Off-Label Uses: This medication is extraordinarily specific. It is exclusively engineered to replace the A-subunit of Factor XIII. It cannot be used to treat patients missing the B-subunit, nor can it be used for Hemophilia A, Hemophilia B, or any other coagulation disorder.

Dosage and Administration Protocols

Because Factor XIII naturally lives in the blood for a very long time, dosing for this medication is exceptionally convenient compared to other bleeding disorders. It is calculated based on the patient’s body weight and is measured in International Units (IU).

Important Adjustments:

• Dose Titration: If a patient experiences a breakthrough bleeding episode while on the standard 28-day schedule, the hematologist may increase the dose or shorten the interval between injections to ensure adequate clot protection.
• Infusion Rate: The medication should be infused at a slow, steady rate, typically not exceeding 1 to 2 mL per minute, to prevent discomfort and reduce the risk of an allergic reaction.
• Organ Function: No specific mathematical dosage adjustments are formally required for patients with renal or hepatic impairment, though close clinical monitoring is always advised for patients with chronic organ disease.

Clinical Efficacy and Research Results

Clinical data from global registries and long-term studies spanning 2020 through 2026 highlight the profound, life-changing efficacy of this once-a-month Biologic. In major clinical trials, patients receiving routine prophylaxis with recombinant Factor XIII A-subunit achieved an Annualized Bleeding Rate (ABR) of near zero. Because the medication has such a long half-life, a single monthly infusion successfully maintains Factor XIII trough levels above the 10% threshold required to prevent spontaneous, life-threatening hemorrhages. This highly effective prevention protects patients from permanent joint destruction and significantly improves their overall quality of life.

Safety Profile and Side Effects

Black Box Warning

Factor XIII A-subunit, recombinant does not carry an FDA Black Box Warning. It is generally recognized as a highly safe and well-tolerated therapy when used as directed.

Common side effects (>10%)

Because this medication is highly purified and closely matches the body’s natural proteins, side effects are usually mild. They may include:

• Headache
• Pain in the extremities (arms and legs)
• Mild pain, redness, or swelling at the IV injection site

Serious adverse events

• Thromboembolic Events: While rare, adding concentrated clotting factors to the blood carries a theoretical risk of over-activating the coagulation system, potentially leading to dangerous blood clots in the deep veins, lungs, or brain.
• Severe Hypersensitivity / Anaphylaxis: A severe, life-threatening allergic reaction to the medication or to the trace amounts of yeast proteins used during the laboratory manufacturing process.
• Inhibitor Development: The patient’s immune system may mistakenly recognize the lab-made Biologic as a foreign invader and create neutralizing antibodies (inhibitors). This destroys the medication and leaves the patient vulnerable to bleeding.

Management Strategies

If a patient develops signs of a severe allergic reaction (such as chest tightness, difficulty breathing, facial swelling, or severe dizziness) during an infusion, the therapy must be stopped instantly, and emergency medications like epinephrine must be administered. If a patient experiences unexpected bleeding despite sticking to their monthly schedule, the healthcare provider must urgently perform a blood test to check for the presence of neutralizing inhibitors.

Research Areas

Given that congenital Factor XIII deficiency affects only about 1 in 2 to 3 million people worldwide, hematology research relies heavily on international cooperation. Current research focuses on long-term safety registries, tracking patients over decades to confirm that the monthly recombinant therapy continues to prevent early-onset arthritis and neurological damage without increasing the risk of blood clots as patients age. Furthermore, scientists are investigating improved laboratory diagnostic methods to help hospitals quickly distinguish between A-subunit and B-subunit deficiencies at birth.

Disclaimer: These studies regarding long-term recombinant factor XIII safety and improved subunit-specific diagnosis are still evolving and are not yet applicable to practical or professional clinical scenarios. While monthly prophylaxis is well supported and laboratory phenotyping of FXIII-A versus FXIII-B deficiency is scientifically valid, claims of decades-long global registry certainty, guaranteed prevention of arthritis or neurologic damage, and definitive lifetime clot-risk safety are speculative and may not be supported by sufficient evidence.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Specific Factor XIII Assays: Standard bleeding tests (like PT and aPTT) will appear completely normal in patients with Factor XIII deficiency. Specialized clot solubility tests or specific Factor XIII antigen tests are required to confirm the diagnosis.
• Genotyping: DNA testing is strongly recommended to definitively confirm that the patient is specifically missing the A-subunit, as this drug will not work for B-subunit mutations.
• Baseline Allergy Check: Screening for known, severe allergies to yeast, as the medication is synthesized using a specialized yeast cell line.

Precautions during treatment

• Thrombosis Vigilance: Patients should be educated on the warning signs of blood clots, especially if they have other risk factors for heart disease or are preparing for a major surgery that requires prolonged bed rest.
• Regular Monitoring: Even though the drug is taken monthly, patients still require regular hematology check-ups to ensure the dosage remains appropriate as their body weight changes.

“Do’s and Don’ts” List

• Do infuse your medication strictly on time, every 28 days, as prescribed by your hematology team.
• Do keep an accurate, detailed calendar or diary of all your infusions and any unusual bruising, and share this with your doctor.
• Do treat any suspected head trauma as a severe medical emergency, even if it seems minor, and go to the emergency room immediately.
• Don’t use this medication if your doctor has diagnosed you with congenital Factor XIII B-subunit deficiency.
• Don’t take pain medications containing aspirin, ibuprofen, or naproxen (NSAIDs), as these interfere with blood platelets and increase the risk of bleeding. Use acetaminophen instead.
• Don’t participate in high-impact contact sports (like football or hockey) without explicit clearance from your medical team.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. This content is not intended to be a substitute for professional medical diagnosis, treatment protocols, or clinical judgment. Always seek the advice of your hematologist, physician, or other qualified health provider with any questions you may have regarding a rare bleeding disorder or before making any changes to your prescribed treatment regimen.